KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer

André T., Pietrantonio F., Avallone A., Gumus M., Wyrwicz L., Kim J. G., ...Daha Fazla

Future Oncology, cilt.19, sa.37, ss.2445-2452, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 19 Sayı: 37
  • Basım Tarihi: 2023
  • Doi Numarası: 10.2217/fon-2022-1105
  • Dergi Adı: Future Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2445-2452
  • Anahtar Kelimeler: favezelimab, MK-4830, MSI-H/dMMR colorectal cancer, pembrolizumab, quavonlimab, vibostolimab
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Robust clinical activity has been observed with the immune checkpoint inhibitor pembrolizumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). However, given the response rate of 45% and a median progression-free survival of 16.5 months with first-line pembrolizumab demonstrated in KEYNOTE-177, there is room for improvement. Targeting a second immune receptor, such as CTLA-4, LAG-3, TIGIT, or ILT-4 may improve efficacy of PD-1 inhibition. Here we describe the design and rationale for the open-label, randomized, phase II KEYSTEP-008 trial, which will evaluate the efficacy and safety of pembrolizumab-based combination therapy compared with pembrolizumab monotherapy in chemotherapy-refractory (cohort A) or previously untreated (cohort B) MSI-H/dMMR mCRC.